加载中
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
前收盘价
US$1.25
+US$0.13 · +11.61%
盘后
US$1.25
US$0.00 · 0.00%
10月12日 19:34 ET
盘中时间采用ET。市场数据可能有所延迟。
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
日内区间
当前US$1.25
52周区间
当前US$1.25
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
43
合理估值
情绪
57
多空交织
风险
82
极高风险
动量
16
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
日内区间
当前US$1.25
52周区间
当前US$1.25
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 62.25万 USD | 391.52万 USD | 681.2万 USD | 3421.82万 USD | 9788.56万 USD |
| 销货成本 | 22.24万 USD | 99.91万 USD | 418.49万 USD | 548.11万 USD | 1157.49万 USD |
| 毛利 | 40.01万 USD | 291.6万 USD | 262.71万 USD | 2873.71万 USD | 8631.07万 USD |
| 研究与开发 | 1913.72万 USD | 2097.96万 USD | 2296.26万 USD | 1743.81万 USD | 1496.19万 USD |
| 销售、一般及管理费用 | 1143.94万 USD | 2064.05万 USD | 2114.03万 USD | 2160.76万 USD | 2494.84万 USD |
| 营业费用 | 3168.35万 USD | 4299.73万 USD | 4533.33万 USD | 5571.7万 USD | 4024.57万 USD |
| 利息收入 | 29.29万 USD | 109.18万 USD | 116.19万 USD | 70.4万 USD | 4.56万 USD |
| 折旧和摊销 | 110.68万 USD | 137.73万 USD | 123.05万 USD | 128.27万 USD | 33.54万 USD |
| 营业利润 | −3128.34万 USD | −4008.13万 USD | −4270.62万 USD | −2697.98万 USD | 4606.5万 USD |
| 净利润 | −4689.59万 USD | −3763.9万 USD | −3533.29万 USD | −1423.82万 USD | 3665.86万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$180
上涨空间 14300.00%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年1月2日 | 1:30 | — | — |
已生效 2026年1月2日
1:30
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
